CNS and Neurodegeneration Biomarkers: In This Market, Speed Is the Product
Ultra-sensitive multiplex immunoassay technology now detects low-abundance biomarkers in complex matrices like cerebrospinal fluid, enabling earlier-stage Alzheimer’s and neurodegenerative disease research that simply wasn’t possible a few years ago. p-Tau 217 went...
Next-Generation Sequencing: The Growth Moved. Did Your Sales Strategy Move With It?
NGS isn’t "next gen" anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re fighting a...
Lab Automation and Decentralized Labs: Your Customers’ Labs Changed. Has Your Pricing Model?
Labs are getting smaller, more automated, and more distributed. Instruments are shrinking and handling more of the manual work themselves. Research hubs outside the traditional life science centers are standing up modular, flexible labs instead of building large...
Pharmacodynamic Biomarker Services: The Fastest Path to Revenue Isn’t the Biotech Sponsor
Biomarker-guided drug development is now structural, not a passing trend; pharma and biotech companies rely on PD biomarkers to select doses, prove mechanism of action, and stratify patients across oncology, immunology, neurology, and rare disease. If you provide...
Gene Editing and CRISPR Reagents: One Market, Two Very Different Sales Cycles
Genome editing is moving from a research tool into therapeutic development pipelines, and that shift is creating real, recurring demand for guide RNAs, delivery reagents, and validation kits. It’s also creating a commercial trap for reagent companies that don’t...
AI-Native Lab Tools: Sell the Capability, Not the Buzzword
Every instrument vendor, every kit company, and every informatics platform now claims to be “AI-powered.” Which means the phrase has stopped doing any commercial work for you. Technical buyers have heard it enough times that it now triggers skepticism instead of...
Single-Cell and 3D/Organoid Systems: Two Markets Wearing One Label
Cell biology is the largest single technology segment in the life science tools market, and “cell biology” is exactly the kind of label that flattens two very different sales motions into one generic pitch. Single-cell sequencing resolves heterogeneity inside a...
Spatial Biology and Multi-Omics: Turning a Breakthrough Platform Into a Repeatable Sales Engine
Spatial transcriptomics, spatial proteomics, and mass spectrometry imaging are converging fast. Researchers can now map gene and protein expression directly inside intact tissue, something no bulk, homogenized sample could ever show them. That’s a genuine scientific...
We cannot wait for the next wave of VC or PE money to solve commercial problems.
I've spent the last several months at life science conferences, dinners, and networking events, talking to founders, CEOs, and investors. And I keep hearing the same thing, just in different rooms. Investors are stuck with Portfolios they can't exit. Which means less...
Are You Wasting Your Money at SLAS Boston?
SLAS Boston is expensive. Booth space. Freight. Travel. Hotels. Sponsorships. Swag.For many life science companies, the total investment quietly creeps into six figures. The real question executives should be asking right now isn’t: “How was the show?” It’s: Did it...